Abstract: An extract composition derived from the peel of a banana and the method for producing the extract composition. An aqueous solvent is combined with the peel of a banana. If the banana is unripe, a base is also added. The mixture is homogenized and allowed to react at least until a black supernatant appears. The entire slurry is filtered. The resulting extract is used alone or combined with a cream or ointment. Medicinal benefits of the extract include relief from pain, swelling, itching, bruising, wrinkles, and sunburn.

Abstract: The subject invention pertains to materials and methods for inhibiting bacterial growth. Specifically provided are compounds which control bacteria by interfering with cell wall synthesis.

Abstract: Novel 4-substituted-1,2-naphthoquinones, pharmaceutical unit dosage forms containing 4-substituted-1,2-naphthoquinones, and uses of 4-substituted-1,2-naphthoquinones to inhibit the growth of cancer cells are disclosed.

Abstract: An extract composition derived from the peel of a banana and the method for producing the extract composition. An aqueous solvent is combined with the peel of a banana. If the banana is unripe, a base is also added. The mixture is homogenized and allowed to react at least until a black supernatant appears. The entire slurry is filtered. The resulting extract is used alone or combined with a cream or ointment. Medicinal benefits of the extract include relief from pain, swelling, itching, bruising, wrinkles, and sunburn.

Abstract: A method for treating skin conditions, such as rosacea and sensitive skin, that manifest as a tendency towards flushing and blushing is provided. Also provided herein, are compositions for the treatment of rosacea and sensitive skin that are comprised of at least one antioxidant selected from the following groups of antioxidants: (a) phenolic compounds that contain at least one hydroxyl group connected directly to a benzene ring and to another unsaturated chemical grouping, (b) sulfur-containing compounds that contain at least one sulfhydryl groups or sulfur-containing compounds that contain at least one disulfide group, or (c) polyene compounds that have conjugated systems of double bonds.

Abstract: Compounds of general formula (1) ##STR1## are described wherein Y is a halogen atom or a group --OR.sup.1, where R.sup.1 is an optionally substituted alkyl group; X is --O--, --S-- or --N(R.sup.7)--, where R.sup.7 is a hydrogen atom or an alkyl group; R.sup.2 is an optionally substituted cycloalkyl or cycloalkenyl group; R.sup.3 and R.sup.4, which may be the same or different, is each a hydrogen atom or an alkyl, --CO.sub.2 R.sup.8 (where R.sup.8 is a hydrogen atom or an alkyl, aryl, or aralkyl group), --CONR.sup.9 R.sup.10 (where R.sup.9 and R.sup.10 which may be the same or different is each a hydrogen atom or an alkyl, aryl or aralkyl group), --CSNR.sup.9 R.sup.10, --CN, --CH.sub.2 CN group; Z is --(CH.sub.2).sub.n -- (where n is zero or an integer 1, 2 or 3; R.sup.5 is an optionally substituted monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms; R.sup.

Abstract: Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.

Abstract: A compound of the formula ##STR1## useful for treating vitamin D dependent disorders.

Abstract: Methods for inhibiting the secretion of .beta.-amyloid peptide (.beta.AP) from cells comprise administering to the cells certain compounds which inhibit the activity of an approximately 31 kD protease involved in .beta.AP secretion. The 31 kD protease has been designated Cathepsin Y. Screening methods for .beta.AP inhibitors rely on determining the activity of test compounds in the presence of Cathepsin Y and a suitable peptide substrate. This invention is also directed to a nucleic acid sequence that encodes Cathepsin Y and the expression and isolation of Cathepsin Y.

Abstract: Pinitol and derivatives and metabolites thereof are useful in nutritional and medicinal compositions for lowering plasma free fatty acid levels and for treating conditions associated with insulin resistance, such as diabetes mellitus and its chronic complications; obesity; hyperlipidemias and dyslipidemias atherosclerosis; hypertension; cardiovascular disease; AIDS; cancer; wasting/cachexia; sepsis; trauma associated with burns, malnutrition, and stress; aging; lupus and other autoimmune diseases; endocrine disease; hyperuricemia, polycystic ovary syndrome and complications arising from athletic activity.

Abstract: Pharmaceutical composition suitable for coating comprising a composition for oral administration in unit dosage form wherein said composition has been coated with from about 0.01% to about 10% by weight of the composition with a volatile aromatic compound selected from the group consisting of 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof.

Abstract: Compounds are provided which are crossreactive with peptides such as those bound by G-protein-linked receptors, together with preparative and therapeutic methods therefor. The compounds have the general structure: ##STR1## wherein at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 or R.sub.6 comprises a chemical functional group which causes the compounds to be crossreactive with the peptide of interest.

Abstract: The subject invention pertains to materials and methods for inhibiting bacterial growth. Specifically provided are compounds which control bacteria by interfering with cell wall synthesis.

Abstract: A cyclohexanol derivative represented by the following general formula (1) and preferably the following general formula (1a): ##STR1## wherein R represents a linear or branched alkyl group having 1 to 5 carbon atoms. The above cyclohexanol derivative imparts satisfactory refrigeration to not only the mouth mucosa but also the skin. Moreover, it is practically odorless. A cool feeling and various cool feeling compositions which are practically odorless can be obtained from the cyclohexanol derivative.

Abstract: A pharmaceutical compound of the formula ##STR1## in which R is hydrogen, halo or F.sub.2 HCO--; or a salt, amide or ester thereof, useful in the treatment of skeletal diseases.

Abstract: Methods for the treatment of metabolic and/or cardiovascular disorders comprising administering to a human in need thereof a therapeutically effective amount of a composition comprising dichloroacetic acid or a pharmaceutically acceptable salt or derivative thereof and a pharmaceutically acceptable mixture of carbonate and bicarbonate ions, the weight ratio of dichloroacetic acid, derivative or salt thereof to the mixture of carbonate and bicarbonate ions being in the range of from about 100:1 to about 0.01:1.

Abstract: Compounds of the formula ##STR1## where the dotted line represents a bond or the absence of a bond, the wavy lines represent bonds which are either in cis or trans configuration; R.sub.1 represents H, or CO--R.sub.2 where R.sub.2 is lower alkyl of 1 to 6 carbons, carbocyclic aryl or heterocyclic aryl; or carbocyclic aryl or heteroaryl substituted lower alkyl group; X represents CO--NR.sub.3 R.sub.4, CH.sub.2 OH, CH.sub.2 OR.sub.5, CH.sub.2 O--COR.sub.6, and CH.sub.2 --NR.sub.3 R.sub.4, where R.sub.3 and R.sub.4 independently are H or lower alkyl, R.sub.5 is lower alkyl of 1 to 6 carbons, and R.sub.6 is lower alkyl of 1 to 6 carbons, carbocyclic aryl or heterocyclic aryl; or carbocyclic aryl or heteroaryl substituted lower alkyl group, and n is an integer between 0 and 8 are capable of lowering intraocular pressure in the eye of a mammal.

Abstract: Pinitol and derivatives and metabolites thereof are useful in nutritional and medicinal compositions for treating conditions associated with insulin resistance, such as diabetes mellitus and its chronic complications; obesity; hyperlipidemias and dyslipidemias atherosclerosis; hypertension; cardiovascular disease; AIDS; cancer; wasting/cachexia; sepsis; trauma associated with burns, malnutrition, and stress; aging; lupus and other autoimmune diseases; endocrine disease; hyperuricemia, polycystic ovary syndrome and complications arising from athletic activity or inactivity.

Abstract: This invention provides a purified retro-retinoid compound characterized by a molecular mass of about 302 daltons. Also provided by this invention is a method of enhancing the growth of a cell in a vitamin A reduced environment which comprises contacting the cell with an effective growth enhancing amount of a compound having a structure: ##STR1## wherein the configuration of the C6, C8, C10 and C12 double bond independently is Z or E and the absolute configuration at C-14 is independently R or S; wherein R.sub.1 is alkyl, alkyl halide, alcohol, ester, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, acid halide, amide, nitrile, or amine; and wherein R.sub.2 is hydroxyl, halide, alkoxy, ester, alkyl, alcohol, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, nitrile, amine, azide, alkyl halide, acid halide, acid azide, or amide; or wherein R.sub.1 and R.sub.2 are replaced by a 14, 15-oxirane group; and wherein the retro structure is alpha or gamma.

Abstract: Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.

Abstract: Substituted hydrindanes and their use in controlling angiogenesis-dependent diseases in warm blooded animals are disclosed.

Abstract: Disclosed is a clear, crystal-free, soap-gelled cosmetic stick composition. The composition includes a soap gelling agent (e.g., sodium stearate); at least two aliphatic polyhydric alcohols that are solvents for the soap gelling agent and that have a relatively small molecular weight and a relatively large molecular weight (e.g., propylene glycol and dipropylene glycol), respectively; a propoxylated ether that is a further solvent for the soap gelling agent, such as a propoxylated butyl ether (e.g., PPG-14 butyl ether); water; and a clarifying agent. The clarifying agent is a mixture of (a) a propoxylated fatty alcohol, such as a propoxylated myristyl ether (e.g., PPG-3 myristyl ether), and (b) a water-soluble, N-substituted aliphatic fatty acid amide surfactant (e.g., a combination of cocamide DEA and cocoyl sarcosine). The stick composition has improved surface aesthetics and improved payout, and has less pullaway from the container.

Abstract: Derivatives of long-chain fatty alcohols, and methods of obtaining them, are provided, as well as pharmaceutical compositions containing derivatives and their uses, in particular in treating or preventing neuro-degenerative illnesses, conditions linked to skin ageing, the phenomena of thrombosis and atherosclerosis, and immune deficiencies.

Abstract: Described is a method of repelling insects by utilizing as active insect repellent ingredient 2,4-dimethyl-4-phenyl-1-butanol or .alpha.-terpinyl methyl ether (ORANGE FLOWER ETHER).

Abstract: A coating varnish composition comprising (A) a polymer obtained by polymerizing (a) at least one unsaturated acid anhydride and (b) at least one other unsaturated monomer, and (B) at least one additive selected from triazole derivatives, benzothiazole derivatives, thiadiazole derivatives, polyethers and carboxylic acid anhydride derivatives, is capable of forming a coating which has no danger of poisoning like the organotin copolymers, shows a coating consuming property and antifouling performance comparable with those of the organotin copolymers and does not gel even when mixed with a copper compound.

Abstract: A compound selected from those of formula (I): ##STR1## wherein: R.sub.1, R'.sub.1 and R.sub.2 are each selected, independently of the others, from hydrogen and an alkyl radical, the two R.sub.2 groups being in the cis position in relation to the rings,and R, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R'a and R'b are as defined in the description,useful therapeutically in the regulation of the secretion of insulin.

Abstract: Novel pesticidal compositions, which are characterized by biodegradability and do not bioaccumulate to an unacceptable level in fats and tissues of animals, fowl and fish, containing active compounds and optionally a carrier suitable for administering said compounds to a pest by contact, ingestion or inhalation, are disclosed. Such compositions comprise in addition to the carrier compounds of the formula ##STR1## where R is H, Cl or other Hal, hydroxyl, lower alkoxyl, lower alkyl, cyano, CONR.sub.2 or NR.sub.2 where R.sub.

Abstract: Ingestible pharmaceutical compositions comprising pharmaceutical actives useful for treating upper gastrointestinal tract distress (e.g., antacid agents) and 3-1-menthoxy propane 1,2-diol in amounts effective for providing a cooling sensation to the throat.

Abstract: This invention relates to a hair-restorer comprising, as an active ingredient, (a) an acyclic branched higher aliphatic hydrocarbon of 20 carbon atoms which may be substituted with hydroxyl group or acyloxy group, or (b) an acyclic branched carboxylic acid of 20 carbon atoms or its derivative and to a process for hair growth.

Abstract: The present invention relates to infection resistant materials and or products made from a molten blend of at least one polymer and a compound having antioxidant, plasticizer and antiviral activity. Additionally, this compound has a hydrophilic lipophilic balance of between 12 and 20. The preferred polymer, polyvinyl chloride, is blended with the antioxidant, plasticizer, antiviral compound NONOXYNOL-9 (.alpha.-nonylphenyl-w-hydroxypoly(oxy-1, 2-ethanediyl) to form the infection resistant material.

Abstract: A suspension type aerosol inhalations containing (a) 0.015 to 5.00% (w/w) of a pyrido[1,2-a]pyrimidine compound of the formula: ##STR1## where R is a n-propyl or allyl group, A is a tetrazolyl or carboxyl group, and n is a whole number of 0 to 2, and (b) 0.015 to 5.00% (w/w) of a fatty acid ester.

Abstract: A clear cosmetic stick is provided whose composition includes from about 10 to 90% of a polyhydric alcohol, from about 1 to about 40% of a soap, from about 1 to about 40% of an alkoxylate copolymer having the formula:[A--CH.sub.2 CH.sub.2 --A].sub.f [(C.sub.2 H.sub.4 O).sub.a (C.sub.3 H.sub.6 O).sub.b (C.sub.2 H.sub.4 O).sub.c (C.sub.3 H.sub.6 O).sub.d ].sub.e [H].sub.gwhereinA is nitrogen;a, b, c and d are independently selected integers ranging from 0 to 200 with the proviso that the sum of a, b, c and d is at least about 50;e is an integer from 1 to 4;f is an integer from 0 to 1-;g is an integer from 0 to 4;and a clarifying agent which is a basic amine present in an effective amount to maintain stick clarity.

Abstract: Injectable contrast agents of great clinical importance for lymphography, characterized by non-water soluble particle sizes between about 5 or 10 nm and about 500 or 900 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are methods for performing percutaneous lymphography using these contrast agents.

Abstract: The present invention relates to a group of compounds which are novel squalene derivatives containing the cyclopropyloxy functionality and which act to inhibit the synthesis of cholesterol in mammals and in fungi.

Abstract: Therapeutic as well as preventive measures to improve cosmetic conditions and to alleviate the symptoms of dermatologic disorders with retinal and its derivatives is disclosed. Cosmetic conditions and dermatologic disorders in humans and domestic animals in which retinal and its derivatives may be useful include age spots, wrinkles, warts, eczema, seborrheic keratoses, acne, oily skin, psoriasis, dandruff, xerosis, inflammatory and pruritic skin, disturbed keratinization skin changes associated with aging and possibly viral infections. Retinal and its derivatives include their stereoisomers, for example, all-trans, 13-cis, 11-cis, 9-cis, 7-cis, 11,13-cis and 9,13-cis vitamin A aldehydes, their hydrate, hemiacetal and acetal forms, and their adduct compounds. Compositions containing retinal or its derivative may be administered systemically such as orally, or topically to the affected areas of the skin.

Abstract: The fibrous polymeric material based on polyvinyl chloride contains at least one antiseptic mercury derivative distributed in its polymeric structure in the form of a substantially molecular and practically non-releasable dispersion.The preferred mercury derivatives have the following general formula: ##STR1## in which Y is H or HgX. If the concentration of the derivative is equal to at least 0.5% by weight, relative to the chlorofiber, the latter has a permanent antiseptic character.This material is obtained by incorporating the above-mentioned derivative into the collodion when the chlorofiber is spun.

Abstract: The present invention relates to a method for inhibiting the phosphatidylinositol cycle in a cell by contacting the cell with certain myo-inositol analogs. Such myo-inositol analogs can also be utilized to treat phosphatidylinositol cycle-dependent conditions. The present invention also provides novel myo-inositol analogs.

Abstract: A coating composition comprising a first phase containing a cross-linkable resin; a second phase containing water; and a third phase containing an insecticide dissolved in a solvent wherein the solvent is immiscible with the first phase and with water.These coating compositions kill insects even after exposure to weather for extended periods of time. They have kill rates higher than prior art compositions containing the same amount of the same insecticide.

Abstract: A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more known uricosurics are also set forth.

Abstract: The present invention relates to a method for inhibiting the phosphatidylinositol cycle in a cell by contacting the cell with certain myo-inositol analogs. Such myo-inositol analogs can also be utilized to treat phosphatidylinositol cycle-dependent conditions. The present invention also provides novel myo-inositol analogs.

Abstract: There are provided new 2,2-difluorocyclopropylethane derivatives of general formula I ##STR1## in which A, B and R.sup.1-5 have the meanings given in the description and processes for their preparation. The compounds of the invention can be used as pesticides, especially against insects and mites.

Abstract: The invention involves a granulating composition composed of an aqueous solution of magnesium sulfate heptahydrate and sodium hexametaphosphate. This composition can be used to prepare granules of ingredients for inclusion in any formulation for which rapid disintegration or dispersion are important factors. It is useful for tablets containing ingredients which are difficult to compress and is particularly useful for formulating swallowable tablets of a single non-soluble ingredient such as calcium carbonate. Disintegration times are markedly decreased.

Abstract: A single-phase, either isotropic or anisotropic formulation is disclosed, which contains perfluorinated oil and one or more surfactant(s), is useful as an excipient for cosmetic and dermatologic formulations and is characterized in that at least one surfactant is selected from those having the following general formula: ##STR1## wherein: R.sub.F is an F--(CF.sub.2 --CF.sub.2).sub.i -- group;X is a group selected from: ##STR2## --(CH.sub.2 --O).sub.K --; and --(CH.sub.2 --S).sub.K --; wherein R.sup.I is a (C.sub.1 -C.sub.4)-alkyl;Y is a group selected from: NH.sub.2 (R.sup.II).sub.2 and N(R.sup.II).sub.4 ; wherein R.sup.II is a hydrogen atom, or a group selected from --CH.sub.2 --CH.sub.2 --OH and (C.sub.1 -C.sub.4)-alkyl;i is an integer comprised within the range of from 3 to 8;i is zero or 1;K is 2.l;l is an integer comprised within the range of from 1 to 10;m is 1 or 2.Such composition is spontaneously formed when the components are simply placed into contact with one another.

Abstract: This invention relates to an aqueous gel comprising a specified capped polyether polymer and a surfactant. Preferred capped polyether polymers can be obtained by modifying a conventional polyether polyol with an alpha-olefin epoxide having an average of about 20 to 45 carbon atoms or mixtures thereof.

Abstract: A method of disinfecting a soft contact lens with a stabilized aqueous hydrogen peroxide solution having a pH between about 5.5 and about 7.5, a hydrogen peroxide content of between about 0.5 and about 6% by weight, and containing between about 0.003 and about 0.03% by weight of diethylene triamine penta(methylenephosphonic acid) or a physiologically compatable salt thereof, and compositions for use in such method.

Abstract: Described are animal control compositions and methods; which compositions comprise citronellyl nitrile, citronellol and, optionally, methyl terpenyl ether, lemon oil, caryophyllene, isopulegol, isopulegyl acetate and quinine or one or more of its salts. The compositions can be used "as is" or in the form of a "controlled release" composition whereby the citronellyl nitrile, citronellol and, optionally, methyl terpenyl ether, lemon oil, caryophyllene, isopulegol, isopulegyl acetate and quinine or one or more of its salts are intimately admixed (alone or with adjuvants including but not limited to other volatile, odorous ingredients) with a polymeric substance such as polyethylene in the form of pellets or functional articles, e.g., garbage bags.

Abstract: Described are animal control compositions and methods; which compositions comprise citronellyl nitrile, citronellol alpha-terpinyl methyl ether and lemon oil and, optionally, caryophyllene, isopulegol, isopulegyl acetate, one or more norbornyl alkyl ethers, one or more 3,4,5,6,6-pentamethyl hexanol-2 derivatives and quinine or one or more of its salts. The compositions can be used "as is" or in the form of a "controlled release" composition whereby the citronellyl nitrile, citronellol, alpha-terpinyl methyl ether and lemon oil and, optionally, the caryophyllene, isopulegol, isopulegyl acetate, one or more norbornyl alkyl ethers, one or more 3,4,5,6,6-pentamethyl hexanol-2 derivatives and quinine or one or more of its salts are intimately admixed (alone or with adjuvants including but not limited to other volatile, odorous ingredients) with a polymeric substance such as polyethylene in the form of pellets or functional articles, e.g., garbage bags.

Abstract: This invention relates to an aqueous gel comprising a specified capped polyether polymer and a surfactant. Preferred capped polyether polymers can be obtained by modifying a conventional polyether polyol with an alpha-olefin epoxide having an average of about 20 to 45 carbon atoms or mixtures thereof.

Abstract: The present invention provides for an oral drug delivery system based on a two phase liquid coacervate system prepared from water and one or more surfactants selected from anionic, cationic, amphoteric, and non-toxic surfactants, polysaccharides, synthetic polymers and polysorbates and their derivatives, and in which a pharmaceutical component is incorporated. The delivery system may be prepared in the form of a microemulsion as well as other forms including encapuslated microparticles. The claimed oral composition is useful to delivery oral dosage forms of drugs, their salts and derivatives thereof; biologicals, enzymes, and other pharmocologically active compositions. A method to prepare the oral drug delivery system is also disclosed.

Abstract: Described are animal control compositions and methods; which compositions comprise lemon oil and .alpha.-terpinyl methyl ether taken alone or taken further together with quinine or salts thereof. The compositions can be used "as is" or in the form of a "controlled release" composition whereby the lemon oil and .alpha.-terpinyl methyl ether taken alone or further together with quinine or a salt thereof are intimately admixed (alone or with adjuvants including but not limited to other volatile, odorous ingredients) with a polymeric substance such as polyethylene in the form of pellets or functional articles, e.g., garbage bags.